Ocular toxicity of recombinant melanoma vaccine (Melimmune)

Document Type

Article

Department

Haematology and Oncology, East Africa

Abstract

The introduction of recombinant vaccines, such as Melimmune, represents a promising advancement in the treatment of melanoma by stimulating the immune system to target malignant cells. However, these therapies may also induce immune-related adverse events, including ocular toxicity. This study examines the potential ocular side effects of the Melimmune vaccine, focusing on the mechanisms by which it may trigger inflammatory responses in ocular tissues. Immune-mediated damage, including retinal inflammation, uveitis, and optic nerve involvement, was evaluated through clinical examinations and imaging techniques. The findings suggest that while ocular toxicity is relatively uncommon, it remains a significant concern, requiring baseline and ongoing ophthalmic assessments during treatment. Proper management, including corticosteroid therapy, can mitigate severe visual outcomes, allowing continued cancer therapy with minimal disruption. This research underscores the importance of interdisciplinary collaboration between oncologists and ophthalmologists in managing the ocular side effects of novel cancer immunotherapies.

Comments

This work was published before the author joined Aga Khan University

Publication (Name of Journal)

Optometry and Vision Science

Link to Full Text

Share

COinS